M
Marek Ancukiewicz
Researcher at Harvard University
Publications - 143
Citations - 20032
Marek Ancukiewicz is an academic researcher from Harvard University. The author has contributed to research in topics: Radiation therapy & Bevacizumab. The author has an hindex of 56, co-authored 142 publications receiving 18390 citations. Previous affiliations of Marek Ancukiewicz include University of Colorado Denver & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).
TL;DR: A comparative study of circulating biomarkers in single arm, phase II studies of sunitinib, cediranib and ramucirumab in pts with advanced HCC finds no biomarker currently exists for appropriately selecting patients with HCC for antiangiogenic therapy.
Journal Article
Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary Phase II study
Andrew X. Zhu,Dushyant V. Sahani,Emmanuelle di Tomaso,Vivek Sindhwani,Marek Ancukiewicz,Sam S. Yoon,Lawrence S. Blaszkowsky,David P. Ryan,Dan G. Duda,Jeffrey W. Clark,Rakesh K. Jain +10 more
TL;DR: LB-139 Abstract LB-139 was submitted as a Late-Breaking Abstract and is embargoed until the time of presentation.
Journal ArticleDOI
Accelerated Partial Breast Irradiation with Low Dose Rate (LDR) Interstitial Implant Brachytherapy (APBI-IB) after Wide Local Excision (WLE): Ten Year Results from a Prospective Trial
Jona A. Hattangadi,Marek Ancukiewicz,Shannon M. MacDonald,M.A. Alm El-Din,M.A. Gadd,Barbara L. Smith,Simon N. Powell,Alphonse G. Taghian +7 more
Journal ArticleDOI
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation
Tracy T. Batchelor,Elizabeth R. Gerstner,Kyrre E. Emblem,Dan G. Duda,Jayashree Kalpathy-Cramer,Matija Snuderl,Marek Ancukiewicz,Pavlina Polaskova,Marco Da Cunha Pinho,Dominique Jennings,Scott R. Plotkin,Andrew S. Chi,April F. Eichler,Jorg Dietrich,Fred H. Hochberg,Christine Lu-Emerson,A. John Iafrate,S. Percy Ivy,Bruce R. Rosen,Jay S. Loeffler,Patrick Y. Wen,A. Greg Sorensen,Rakesh K. Jain +22 more
TL;DR: It is hypothesized that the subset of GBM subjects who experience increased perfusion and improved tumor oxygenation status after anti-VEGF therapy will derive optimal benefit from concurrent chemoradiation and innate anti-tumor immune mechanisms.